Clinical trial · Interventional
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase II Study of Irinotecan for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00003245CI-TRIAL-00035792completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or refractory non-Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| irinotecan hydrochloride | Drug | Irinotecan | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed recurrent or refractory non-Hodgkin's lymphoma * First relapse requires histologic confirmation of relapse * No CNS metastases * No lymphomatous meningitis * Measurable disease PATIENT CHARACTERISTICS: Age: * 15-75 Performance status: * Zubrod 0-2 Life expectancy: * At least 12 weeks Hematopoietic: * Unless due to lymphoma: * Platelet count at least 100,000/mm\^3 * Absolute granulocyte count at least 1,500/mm\^3 * Hemoglobin at least 9 g/dL Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN if liver involvement) Renal: * Creatinine no greater than 2.0 mg/dL * Baseline calcium less than 12 mg/dL Cardiovascular: * No myocardial infarction within 6 months * No congestive heart failure requiring therapy Other: * No history of seizures * No uncontrolled diabetes mellitus (i.e., random blood sugar of at least 250 mg) * No other concurrent severe disease * No uncontrolled infection * HIV negative * No psychoses * No prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cancer of the cervix unless surgically treated and disease free for at least 5 years * Not pregnant or lactating * Effective contraception required of fertile patients PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior bone marrow transplantation Chemotherapy: * No more than 2 prior chemotherapy regimens for treatment of lymphoma * No prior irinotecan, topotecan or aminocamptothecin * At least 3 weeks since prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 3 weeks since prior radiotherapy * Radiotherapy that is not a part of a combined-modality therapy is counted as a regimen (see Chemotherapy) Surgery: * Not specified Other: * No phenytoin, phenobarbital, or other antiepileptic prophylaxis
References
Publications (0)
Data not yet available
No reference posted for this study.